A Randomized Trial of Distal Diuretics versus Dietary Sodium Restriction for Hypertension in Chronic Kidney Disease.

BACKGROUND Distal diuretics are considered less effective than loop diuretics in CKD. However, data to support this perception are limited. METHODS To investigate whether distal diuretics are noninferior to dietary sodium restriction in reducing BP in patients with CKD stage G3 or G4 and hypertension, we conducted a 6-week, randomized, open-label crossover trial comparing amiloride/hydrochlorothiazide (5 mg/50 mg daily) with dietary sodium restriction (60 mmol per day). Antihypertension medication was discontinued for a 2-week period before randomization. We analyzed effects on BP, kidney function, and fluid balance and related this to renal clearance of diuretics. RESULTS A total of 26 patients (with a mean eGFR of 39 ml/min per 1.73 m2) completed both treatments. Dietary sodium restriction reduced sodium excretion from 160 to 64 mmol per day. Diuretics produced a greater reduction in 24-hour systolic BP (SBP; from 138 to 124 mm Hg) compared with sodium restriction (from 134 to 129 mm Hg), as well as a significantly greater effect on extracellular water, eGFR, plasma renin, and aldosterone. Both interventions resulted in a similar decrease in body weight and NT-proBNP. Neither approaches decreased albuminuria significantly, whereas diuretics did significantly reduce urinary angiotensinogen and β2-microglobulin excretion. Although lower eGFR and higher plasma indoxyl sulfate correlated with lower diuretic clearance, the diuretic effects on body weight and BP at lower eGFR were maintained. During diuretic treatment, higher PGE2 excretion correlated with lower free water clearance, and four patients developed mild hyponatremia. CONCLUSIONS Distal diuretics are noninferior to dietary sodium restriction in reducing BP and extracellular volume in CKD. Diuretic sensitivity in CKD is maintained despite lower diuretic clearance. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease (DD), NCT02875886.

[1]  B. Zinman,et al.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.

[2]  J. Sluijter,et al.  Remote sensing and signaling in kidney proximal tubules stimulates gut microbiome-derived organic anion secretion , 2019, Proceedings of the National Academy of Sciences.

[3]  P. Houillier,et al.  Extracellular fluid volume is associated with incident end-stage kidney disease and mortality in patients with chronic kidney disease. , 2019, Kidney International.

[4]  Christine L. Taylor,et al.  Sodium-Intake Reduction and the Food Industry. , 2019, The New England journal of medicine.

[5]  Jackson T. Wright,et al.  Measurement of Blood Pressure in Humans: A Scientific Statement From the American Heart Association. , 2019, Hypertension.

[6]  B. Zinman,et al.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.

[7]  Z. Gaciong,et al.  Performance of 24-hour urinary creatinine excretion-estimating equations in relation to measured 24-hour urinary creatinine excretion in hospitalized hypertensive patients , 2019, Scientific Reports.

[8]  Stephanie M. Mutchler,et al.  New insights regarding epithelial Na+ channel regulation and its role in the kidney, immune system and vasculature , 2019, Current opinion in nephrology and hypertension.

[9]  P. Houillier,et al.  Extracellular Fluid Volume Is an Independent Determinant of Uncontrolled and Resistant Hypertension in Chronic Kidney Disease: A NephroTest Cohort Study , 2018, Journal of the American Heart Association.

[10]  L. Wain,et al.  Phenotypic and pharmacogenetic evaluation of patients with thiazide-induced hyponatremia , 2017, The Journal of clinical investigation.

[11]  A. Layton,et al.  Adaptive changes in GFR, tubular morphology, and transport in subtotal nephrectomized kidneys: modeling and analysis. , 2017, American journal of physiology. Renal physiology.

[12]  M. Chen,et al.  Compensatory Distal Reabsorption Drives Diuretic Resistance in Human Heart Failure. , 2017, Journal of the American Society of Nephrology : JASN.

[13]  G. Navis,et al.  Effects of Vitamin D Receptor Activation and Dietary Sodium Restriction on Residual Albuminuria in CKD: The ViRTUE-CKD Trial. , 2017, Journal of the American Society of Nephrology : JASN.

[14]  Jaivik V. Shah,et al.  Simultaneous quantification of amiloride and hydrochlorothiazide in human plasma by liquid chromatography–tandem mass spectrometry , 2017, Journal of pharmaceutical analysis.

[15]  B. Pitt,et al.  A Randomized Crossover Trial of Dietary Sodium Restriction in Stage 3-4 CKD. , 2017, Clinical journal of the American Society of Nephrology : CJASN.

[16]  D. Stamatialis,et al.  Bioengineered kidney tubules efficiently excrete uremic toxins , 2016, Scientific Reports.

[17]  H. Struijker‐Boudier,et al.  On the Origin of Urinary Renin: A Translational Approach. , 2016, Hypertension.

[18]  J. Izzo,et al.  Is there a preferred diuretic class for patients with renal impairment and hypertension? , 2016, Journal of the American Society of Hypertension : JASH.

[19]  R. Agarwal,et al.  Thiazides are useful agents in CKD. , 2016, Journal of the American Society of Hypertension : JASH.

[20]  Sandosh Padmanabhan,et al.  Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial , 2016, The lancet. Diabetes & endocrinology.

[21]  R. Zatz,et al.  An association of losartan-hydrochlorothiazide, but not losartan-furosemide, completely arrests progressive injury in the remnant kidney. , 2016, American journal of physiology. Renal physiology.

[22]  M. Missler,et al.  Differential response to endothelial epithelial sodium channel inhibition ex vivo correlates with arterial stiffness in humans , 2015, Journal of hypertension.

[23]  E. Morales,et al.  Diverse diuretics regimens differentially enhance the antialbuminuric effect of renin-angiotensin blockers in patients with chronic kidney disease. , 2015, Kidney international.

[24]  R. Blantz,et al.  Handling of Drugs, Metabolites, and Uremic Toxins by Kidney Proximal Tubule Drug Transporters. , 2015, Clinical journal of the American Society of Nephrology : CJASN.

[25]  R. Agarwal,et al.  Thiazides in advanced chronic kidney disease: time for a randomized controlled trial , 2015, Current opinion in cardiology.

[26]  J. Wade,et al.  Integrated compensatory network is activated in the absence of NCC phosphorylation. , 2015, The Journal of clinical investigation.

[27]  K. Tabei,et al.  Renoprotective effects of thiazides combined with loop diuretics in patients with type 2 diabetic kidney disease , 2015, Clinical and Experimental Nephrology.

[28]  R. Agarwal,et al.  Thiazide Diuretics in Chronic Kidney Disease , 2015, Current Hypertension Reports.

[29]  B. Jensen,et al.  Urinary serine proteases and activation of ENaC in kidney—implications for physiological renal salt handling and hypertensive disorders with albuminuria , 2015, Pflügers Archiv - European Journal of Physiology.

[30]  K. Campbell,et al.  Altered dietary salt intake for people with chronic kidney disease. , 2015, The Cochrane database of systematic reviews.

[31]  M. Weir,et al.  The use of thiazides in chronic kidney disease. , 2015, Current hypertension reviews.

[32]  K. Fujisaki,et al.  Impact of combined losartan/hydrochlorothiazide on proteinuria in patients with chronic kidney disease and hypertension , 2014, Hypertension Research.

[33]  David W. Johnson,et al.  A randomized trial of sodium-restriction on kidney function, fluid volume and adipokines in CKD patients , 2014, BMC Nephrology.

[34]  M. Cirillo,et al.  Parallel-Group 8-Week Study on Chlorthalidone Effects in Hypertensives With Low Kidney Function , 2014, Hypertension.

[35]  D. Tarng,et al.  Volume overload correlates with cardiovascular risk factors in patients with chronic kidney disease. , 2014, Kidney international.

[36]  R. Agarwal,et al.  Chlorthalidone for Poorly Controlled Hypertension in Chronic Kidney Disease: An Interventional Pilot Study , 2014, American Journal of Nephrology.

[37]  David W. Johnson,et al.  A randomized trial of dietary sodium restriction in CKD. , 2013, Journal of the American Society of Nephrology : JASN.

[38]  A. Hofman,et al.  Thiazide-associated hyponatremia: a population-based study. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[39]  N. Câmara,et al.  Regression of Albuminuria and Hypertension and Arrest of Severe Renal Injury by a Losartan-Hydrochlorothiazide Association in a Model of Very Advanced Nephropathy , 2013, PloS one.

[40]  R. Zietse,et al.  Urinary Markers of Intrarenal Renin-Angiotensin System Activity In Vivo , 2013, Current Hypertension Reports.

[41]  M. Weir,et al.  Thiazide and Thiazide-like Diuretics: An Opportunity to Reduce Blood Pressure in Patients with Advanced Kidney Disease , 2012, Current Hypertension Reports.

[42]  Maria Blettner,et al.  On the proper use of the crossover design in clinical trials: part 18 of a series on evaluation of scientific publications. , 2012, Deutsches Arzteblatt international.

[43]  O. Mundler,et al.  A Pilot Study Comparing Furosemide and Hydrochlorothiazide in Patients With Hypertension and Stage 4 or 5 Chronic Kidney Disease , 2012, Journal of clinical hypertension.

[44]  G. Navis,et al.  Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial , 2011, BMJ : British Medical Journal.

[45]  R. Freeman,et al.  Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome , 2011, Autonomic Neuroscience.

[46]  R. Carey,et al.  Role of the Intrarenal Renin-Angiotensin-Aldosterone System in Chronic Kidney Disease , 2010, American Journal of Nephrology.

[47]  Y. Oh,et al.  Changes in the Sodium and Potassium Transporters in the Course of Chronic Renal Failure , 2010, Nephron Physiology.

[48]  Koichi Matsumoto,et al.  Antiproteinuric and Blood Pressure‐Lowering Effects of a Fixed‐Dose Combination of Losartan and Hydrochlorothiazide in Hypertensive Patients with Stage 3 Chronic Kidney Disease , 2009, Pharmacotherapy.

[49]  T. Maruyama,et al.  Renoprotect and blood pressure lowering effect of low-dose hydrochlorothiazide added to intensive renin-angiotensin inhibition in hypertensive patients with chronic kidney disease. , 2009, International journal of clinical pharmacology and therapeutics.

[50]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[51]  N. Hollenberg,et al.  Aliskiren Accumulates in Renin Secretory Granules and Binds Plasma Prorenin , 2008, Hypertension.

[52]  G. Navis,et al.  Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. , 2008, Journal of the American Society of Nephrology : JASN.

[53]  F. Vrtovsnik,et al.  Cardiovascular remodelling and extracellular fluid excess in early stages of chronic kidney disease. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[54]  R. Zatz,et al.  Losartan-hydrochlorothiazide association promotes lasting blood pressure normalization and completely arrests long-term renal injury in the 5/6 ablation model. , 2007, American journal of physiology. Renal physiology.

[55]  V. Vallon,et al.  Enhanced passive Ca2+ reabsorption and reduced Mg2+ channel abundance explains thiazide-induced hypocalciuria and hypomagnesemia. , 2005, The Journal of clinical investigation.

[56]  O. Mundler,et al.  A randomized trial of furosemide vs hydrochlorothiazide in patients with chronic renal failure and hypertension. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[57]  L. P. Van den Heuvel,et al.  Abnormalities of Gq-mediated cell signaling in Bartter and Gitelman syndromes. , 2001, Kidney international.

[58]  P. Fernández-Llama,et al.  Altered expression of Na transporters NHE-3, NaPi-II, Na-K-ATPase, BSC-1, and TSC in CRF rat kidneys. , 1999, American journal of physiology. Renal physiology.

[59]  A. Hughes,et al.  Thiazide-induced vasodilation in humans is mediated by potassium channel activation. , 1998, Hypertension.

[60]  M. Polenaković,et al.  Long-term diuretic therapy in patients with chronic renal failure. , 1997, Clinical nephrology.

[61]  A. Danser,et al.  Renin-angiotensin system components in the interstitial fluid of the isolated perfused rat heart. Local production of angiotensin I. , 1997, Hypertension.

[62]  M. Lishner,et al.  Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. , 1996, Archives of internal medicine.

[63]  D. Fliser,et al.  Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. , 1994, Kidney international.

[64]  M. Safar,et al.  Arterial effects of salt restriction in hypertensive patients. A 9-week, randomized, double-blind, crossover study , 1992, Journal of hypertension.

[65]  V. A. Skoutakis,et al.  Clinical efficacy, safety, and pharmacokinetics of indapamide in renal impairment. , 1983, American heart journal.

[66]  R. Nanra,et al.  DOUBLE-BLIND TRIAL OF ANTIHYPERTENSIVE EFFECT OF CHLOROTHIAZIDE IN SEVERE RENAL FAILURE , 1979, The Lancet.

[67]  M. Hills,et al.  The two-period cross-over clinical trial. , 1979, British journal of clinical pharmacology.

[68]  N. Bank,et al.  Use of diuretics in treatment of hypertension secondary to renal disease. , 1978, Archives of internal medicine.

[69]  W. Bennett,et al.  Commentary , 1977, A Thrice-Told Tale.

[70]  W. Bennett,et al.  Do diuretics have antihypertensive properties independent of natriuresis? , 1977, Clinical pharmacology and therapeutics.

[71]  C. Reed,et al.  Lead in dringking water. , 1967, Lancet.

[72]  F. Reubi,et al.  Effects of Reduced Glomerular Filtration Rate on Responsiveness to Chlorothiazide and Mercurial Diuretics , 1961, Circulation.

[73]  G. Schreiner CHLOROTHIAZIDE IN RENAL DISEASE , 1958, Annals of the New York Academy of Sciences.

[74]  G. Schreiner,et al.  Effect of chlorothiazide on the edema of cirrhosis, nephrosis, congestive heart failure and chronic renal insufficiency. , 1957, The New England journal of medicine.

[75]  D. Ellison,et al.  Diuretic Resistance. , 2017, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[76]  A. Fellet,et al.  Amiloride-sensitive and amiloride-insensitive kaliuresis in advanced chronic kidney disease. , 2008, Journal of nephrology.

[77]  E. Mutschler,et al.  Limitation on the use of amiloride in early renal failure , 2004, European Journal of Clinical Pharmacology.

[78]  A. Cockett,et al.  Prostaglandins in semen and their relationship to male fertility: a study of 145 men. , 1984, Fertility and sterility.

[79]  C. H. Lockwood Diuretic therapy. , 1961, Medical services journal, Canada.